Raymond J. Hohl, MD, PhD, was not too long ago named chair of the Most cancers Middle Administrators Committee for the Large Ten Most cancers Analysis Consortium (Large Ten CRC).
Raymond J. Hohl MD, PhD, was not too long ago named chair of the Most cancers Middle Administrators Committee for the Large Ten Most cancers Analysis Consortium (Large Ten CRC). On this position, Dr. Hohl will assist information strategic priorities for the Large Ten CRC because the consortium enters its second decade. Dr. Hohl has been a member of the management committee for the reason that consortium’s founding in 2013 and succeeds Howard Bailey, MD, director of the College of Wisconsin Carbone Most cancers Middle, because the committee chair.
Could 13, 2024
Dr. Hohl is director of the Penn State Most cancers Institute, professor of drugs and pharmacology on the Penn State School of Drugs, Penn State College, and holds a college professorship in medication. Dr. Hohl is a medical oncologist, hematologist, and scientific pharmacologist with broad expertise as a scientific and translational researcher.
Dr. Hohl commented, “I’m honored to have been elected to this position and am grateful to my predecessors for his or her exemplary work. Because the Large Ten Most cancers Analysis Consortium continues in its second decade there’s a lot to be executed. I’m significantly enthusiastic in regards to the ongoing efforts to increase the consortium from its present 15 members to incorporate the brand new Large Ten establishments. We are going to foster an setting for the event and operating of revolutionary investigator-initiated research that match new with seasoned scientific scientists throughout our member establishments.”
Dr. Hohl started his profession on the College of Iowa School of Drugs in 1991. Over time, he served in quite a lot of management roles on the College of Iowa, together with director of the division of hematology, oncology and blood and marrow transplantation on the Roy J. and Lucille A. Carver School of Drugs; director of the fellowship program, division of hematology, oncology and blood and marrow transplantation; affiliate director for scientific analysis and affiliate director for scientific translational analysis on the Holden Complete Most cancers Middle; and affiliate chair within the division of inside medication.
Dr. Hohl was named director of Penn State Most cancers Institute in 2013.
Should you’re having hassle accessing this content material, or would really like it in one other format, please electronic mail the Penn State School of Drugs net division.
